HK1149024A1 - Novel antibodies inhibiting c-met dimerization, and uses thereof c-met - Google Patents

Novel antibodies inhibiting c-met dimerization, and uses thereof c-met

Info

Publication number
HK1149024A1
HK1149024A1 HK11103062.4A HK11103062A HK1149024A1 HK 1149024 A1 HK1149024 A1 HK 1149024A1 HK 11103062 A HK11103062 A HK 11103062A HK 1149024 A1 HK1149024 A1 HK 1149024A1
Authority
HK
Hong Kong
Prior art keywords
met
dimerization
novel antibodies
antibodies inhibiting
inhibiting
Prior art date
Application number
HK11103062.4A
Other languages
English (en)
Chinese (zh)
Inventor
‧格奇
Original Assignee
皮埃爾法布雷醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38871713&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1149024(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 皮埃爾法布雷醫藥公司 filed Critical 皮埃爾法布雷醫藥公司
Publication of HK1149024A1 publication Critical patent/HK1149024A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
HK11103062.4A 2007-07-12 2011-03-28 Novel antibodies inhibiting c-met dimerization, and uses thereof c-met HK1149024A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92978907P 2007-07-12 2007-07-12
EP07301231A EP2014681A1 (fr) 2007-07-12 2007-07-12 Nouveaux anticorps à inhibition de dimérisation c-met, et utilisations correspondantes
US2063908P 2008-01-11 2008-01-11
PCT/EP2008/059026 WO2009007427A2 (fr) 2007-07-12 2008-07-10 Nouveaux anticorps inhibant la dimérisation de c-met et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
HK1149024A1 true HK1149024A1 (en) 2011-09-23

Family

ID=38871713

Family Applications (3)

Application Number Title Priority Date Filing Date
HK11103062.4A HK1149024A1 (en) 2007-07-12 2011-03-28 Novel antibodies inhibiting c-met dimerization, and uses thereof c-met
HK14106929.7A HK1193619A1 (zh) 2007-07-12 2011-03-28 抑制 二聚化的新型抗體及其用途
HK14106930.4A HK1193620A1 (zh) 2007-07-12 2011-03-28 抑制 二聚化的新型抗體及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK14106929.7A HK1193619A1 (zh) 2007-07-12 2011-03-28 抑制 二聚化的新型抗體及其用途
HK14106930.4A HK1193620A1 (zh) 2007-07-12 2011-03-28 抑制 二聚化的新型抗體及其用途

Country Status (36)

Country Link
US (6) US8329173B2 (fr)
EP (6) EP2014681A1 (fr)
JP (4) JP5562844B2 (fr)
KR (4) KR101719084B1 (fr)
CN (4) CN103509113B (fr)
AR (4) AR067517A1 (fr)
AU (1) AU2008274171B2 (fr)
BR (1) BRPI0815564B8 (fr)
CA (4) CA2888691C (fr)
CL (1) CL2008002015A1 (fr)
CO (1) CO6170364A2 (fr)
CY (1) CY1116608T1 (fr)
DK (1) DK2188312T3 (fr)
ES (5) ES2686335T3 (fr)
HK (3) HK1149024A1 (fr)
HR (1) HRP20150887T1 (fr)
HU (1) HUE026026T2 (fr)
IL (5) IL203114A (fr)
MA (1) MA31977B1 (fr)
ME (1) ME02341B (fr)
MX (3) MX345391B (fr)
MY (1) MY158756A (fr)
NZ (4) NZ599959A (fr)
PA (1) PA8789201A1 (fr)
PH (3) PH12018502038A1 (fr)
PL (1) PL2188312T3 (fr)
PT (1) PT2188312E (fr)
RS (1) RS54197B1 (fr)
RU (1) RU2552161C2 (fr)
SA (1) SA08290423B1 (fr)
SG (1) SG183015A1 (fr)
SI (1) SI2188312T1 (fr)
TN (1) TN2010000016A1 (fr)
TW (4) TWI549965B (fr)
WO (1) WO2009007427A2 (fr)
ZA (1) ZA201000966B (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2143441A1 (fr) 2008-07-08 2010-01-13 Pierre Fabre Medicament Combinaison d'antagoniste c-MET et composé d'aminihétéroaryl pour le traitement du cancer
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
US20140112911A9 (en) * 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
EP2417159A1 (fr) 2009-04-07 2012-02-15 Roche Glycart AG Anticorps anti-erbb-3/anti-c-met bispécifiques
CN102361883A (zh) 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 双特异性抗-ErbB-1/抗-c-Met抗体
EP2287197A1 (fr) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anticorps anti-cMET et son utilisation pour la détection et le diagnostic du cancer
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
WO2011110642A2 (fr) * 2010-03-10 2011-09-15 Genmab A/S Anticorps monoclonaux contre c-met
JP2013534515A (ja) * 2010-06-01 2013-09-05 モナシュ ユニバーシティ プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体
EP2402370A1 (fr) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Nouvel anticorps pour le diagnostic et/ou le pronostic du cancer
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
AU2011295919A1 (en) 2010-08-31 2013-03-07 Genentech, Inc. Biomarkers and methods of treatment
EP2611928B1 (fr) * 2010-09-03 2016-04-27 Academia Sinica Anticorps anti-c-met et procédés d'utilisation de ceux-ci
WO2012042026A1 (fr) 2010-09-30 2012-04-05 Ablynx Nv Matières biologiques associées à c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CN103764678A (zh) 2010-11-03 2014-04-30 阿尔金-X公司 c-Met抗体组合
BR112013013003A2 (pt) 2010-11-24 2016-08-09 Glaxo Group Ltd proteína de ligação de antígeno, e, composição farmacêutica
KR101444837B1 (ko) 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
BR112013032145B1 (pt) 2011-06-23 2022-09-20 Ablynx N.V Técnicas para prever, detectar e reduzir interferência de proteína não especifica em ensaios envolvendo domínios variáveis únicos de imunoglobulina
ES2759936T3 (es) * 2011-06-23 2020-05-12 Ablynx Nv Proteínas de unión a albúmina sérica
US20130004484A1 (en) * 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
AR087918A1 (es) 2011-09-19 2014-04-23 Genentech Inc Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
US9201074B2 (en) 2011-09-20 2015-12-01 Eli Lilly And Company Anti-c-Met antibodies
CN106046161B (zh) 2011-09-30 2019-09-13 埃博灵克斯股份有限公司 与C-Met相关的生物物质
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
KR101865223B1 (ko) * 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
JP2014533700A (ja) 2011-11-21 2014-12-15 ジェネンテック， インコーポレイテッド 抗ｃ−ＭＥＴ抗体の精製
EP2785741A1 (fr) 2011-12-02 2014-10-08 Cancer Research Technology Limited Anticorps dirigés contre le récepteur de hgf et leurs utilisations
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
US9376485B2 (en) 2012-02-29 2016-06-28 The Brigham And Women's Hospital, Inc. Neutralizing antibody for epstein barr virus-associated disease
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
JP6429771B2 (ja) 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ｃ−Ｍｅｔに結合する抗原結合タンパク質
KR101938698B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
KR101938699B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
CN104903726A (zh) * 2012-09-05 2015-09-09 Jsr株式会社 对细胞的上皮性维持起作用的物质的筛选方法
PL2766048T3 (pl) 2012-10-12 2015-05-29 Medimmune Ltd Pirolobenzodiazepiny i ich koniugaty
EP2727941A1 (fr) 2012-11-05 2014-05-07 MAB Discovery GmbH Procédé pour la production d'anticorps multispécifiques
US20150259430A1 (en) 2012-11-05 2015-09-17 Mab Discovery Gmbh Method for the production of multispecific antibodies
WO2014074907A1 (fr) * 2012-11-09 2014-05-15 Indi Molecular, Inc. Agents de capture spécifiques de c-met, compositions et procédés d'utilisation et de fabrication
KR101911048B1 (ko) 2013-01-29 2018-10-24 삼성전자주식회사 ｐ５３ 활성화제 및 ｃ－Ｍｅｔ 억제제를 포함하는 병용 투여용 약학 조성물
BR112015018418A2 (pt) 2013-02-22 2017-07-18 Hoffmann La Roche métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
AU2014225661A1 (en) 2013-03-06 2015-09-10 Merrimack Pharmaceuticals, Inc. Anti-c-Met tandem Fc bispecific antibodies
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102139607B1 (ko) * 2013-04-01 2020-07-30 삼성전자주식회사 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
WO2015031614A1 (fr) * 2013-08-28 2015-03-05 Abbvie Inc. Dosage de la cmet soluble
WO2015031626A1 (fr) 2013-08-28 2015-03-05 Abbvie Inc. Dosage de cmet soluble
WO2015051159A1 (fr) * 2013-10-02 2015-04-09 The Rockefeller University Anticorps de protofibrilles amyloïdes et leurs procédés d'utilisation
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
JP2017524371A (ja) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド Ｍｉｔバイオマーカーとその使用方法
EP3193940A1 (fr) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
BR112017005202A2 (pt) 2014-09-16 2017-12-12 Symphogen As anticorpos anti-met e composições
WO2016053610A1 (fr) * 2014-10-03 2016-04-07 Academia Sinica Anticorps contre les formes pathologiques de tdp-43 et utilisations de ces derniers
EP3200825A4 (fr) 2014-10-03 2018-03-21 Academia Sinica Anticorps contre les formes pathologiques de tdp-43 et utilisations de ces derniers
EP3221468B1 (fr) * 2014-11-20 2020-03-25 Stichting Katholieke Universiteit Nouveau mutant intracellulaire à activation automatique de met
US10398774B2 (en) 2014-12-09 2019-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against AXL
US11426468B2 (en) 2014-12-19 2022-08-30 Ablynx N.V. Cysteine linked nanobody dimers
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
US20180057595A1 (en) * 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
CN107646039B (zh) 2015-04-02 2022-04-15 埃博灵克斯股份有限公司 具有有效抗hiv活性的双特异性cxcr4-cd4多肽
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
WO2017062496A2 (fr) * 2015-10-05 2017-04-13 University Of Virginia Patent Foundation Anticorps anti-sas1b, procédés d'utilisation associés, et compositions et procédés de détection et de traitement du cancer
EP3371223B1 (fr) 2015-11-03 2021-03-10 Merck Patent GmbH Anticorps bispécifiques pour une plus grande sélectivité et une meilleure inhibition des tumeurs, et utilisations associées
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
PT3458102T (pt) 2016-05-17 2020-08-17 Abbvie Inc Conjugados de fármacos com anticorpo anti-cmet e métodos para o seu uso
AR108975A1 (es) * 2016-07-06 2018-10-17 Celgene Corp Anticuerpos con baja inmunogenicidad y sus usos
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
WO2019018538A1 (fr) * 2017-07-20 2019-01-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Anticorps recombinants se liant à cd123
WO2019117691A1 (fr) * 2017-12-15 2019-06-20 경북대학교 산학협력단 Peptides se liant à cd44v6 et utilisation correspondante
KR102194025B1 (ko) 2017-12-15 2020-12-22 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
CN112040769B (zh) * 2018-03-24 2023-05-16 瑞泽恩制药公司 用于产生针对肽-mhc复合物的治疗抗体的经过基因修饰的非人动物、制造方法和用途
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
WO2020014306A1 (fr) 2018-07-10 2020-01-16 Immunogen, Inc. Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
CN114340684A (zh) 2019-09-16 2022-04-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
WO2022079211A1 (fr) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugués
US20240117061A1 (en) * 2020-12-16 2024-04-11 Wuhan Yzy Biopharma Co., Ltd. Anti-bcma antibody, preparation method therefor and application thereof
CN112679614B (zh) * 2021-01-15 2022-08-16 广东安普泽生物医药股份有限公司 用于特异性结合rankl靶向治疗药物的抗体及其用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN112946279A (zh) * 2021-03-17 2021-06-11 扬州大学 一种基于油水界面自组装的三明治sers免疫传感器检测***患者血清生物标志物方法
AR125473A1 (es) 2021-04-29 2023-07-19 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
WO2023129928A2 (fr) * 2021-12-27 2023-07-06 Academia Sinica Anticorps spécifique de la protéine de spicule du sars-cov-2 et ses utilisations
WO2024131846A1 (fr) * 2022-12-20 2024-06-27 Hansoh Bio Llc Anticorps, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique associée

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2840250C2 (de) 1978-09-15 1983-01-20 Siemens AG, 1000 Berlin und 8000 München Schaltungsanordnung für eine leitungsgespeiste Lautfernsprechstation
US4424200A (en) * 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US7227002B1 (en) * 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2003072736A2 (fr) * 2002-02-21 2003-09-04 Duke University Reactifs et methodes therapeutiques de maladies auto-immunes
BRPI0407446A (pt) * 2003-02-13 2006-01-31 Pharmacia Corp Anticorpos para c-met para o tratamento de cânceres
JP5416338B2 (ja) * 2003-05-09 2014-02-12 デューク ユニバーシティ Ｃｄ２０特異的抗体およびその使用方法
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP2336178A1 (fr) 2003-12-11 2011-06-22 Genentech, Inc. Procédés et compositions pour l'inhibition de dimérisation et activation C-Met
DK1773885T3 (da) * 2004-08-05 2010-08-16 Genentech Inc Humaniserede anti-c-met-antagonister
US20060094059A1 (en) 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
CN101155831B (zh) * 2005-02-10 2015-08-19 贝勒研究院 抗干扰素α单克隆抗体及其使用方法
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
EP2397498A3 (fr) 2005-07-18 2013-11-27 Amgen, Inc Anticorps humains à neutralisation anti-B7RP1
EP2311876A3 (fr) 2005-07-28 2011-04-27 Novartis AG Anticorps monoclonal spécifique du M-CSF et ses utilisations
DK1981981T3 (da) 2006-02-06 2011-09-26 Metheresis Translational Res Sa Monoklonalt anti-met antistof, fragmenter og vektorer deraf til behandling af tumorer, samt tilsvarende produkter
WO2007126799A2 (fr) 2006-03-30 2007-11-08 Novartis Ag Compositions et procédés d'utilisation associés à des anticorps de c-met
EP2143441A1 (fr) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combinaison d'antagoniste c-MET et composé d'aminihétéroaryl pour le traitement du cancer
WO2010064089A1 (fr) 2008-12-02 2010-06-10 Pierre Fabre Medicament Nouvel anticorps anti-cmet
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)

Also Published As

Publication number Publication date
RU2552161C2 (ru) 2015-06-10
IL203114A (en) 2015-03-31
TW201605891A (zh) 2016-02-16
CA2888691A1 (fr) 2009-01-15
DK2188312T3 (en) 2015-08-03
MA31977B1 (fr) 2011-01-03
AR109660A2 (es) 2019-01-09
IL223106A0 (en) 2012-12-31
MX353449B (es) 2018-01-08
KR20150070451A (ko) 2015-06-24
CA2694418A1 (fr) 2009-01-15
JP2014113154A (ja) 2014-06-26
EP2415784B1 (fr) 2018-06-13
EP2535356B1 (fr) 2018-06-13
KR20100044212A (ko) 2010-04-29
AU2008274171B2 (en) 2014-02-27
NZ599958A (en) 2013-11-29
CA2888691C (fr) 2023-01-03
TWI602829B (zh) 2017-10-21
HK1193619A1 (zh) 2014-09-26
ES2686693T3 (es) 2018-10-19
RU2010104633A (ru) 2011-08-20
PA8789201A1 (es) 2009-08-26
CA2982484A1 (fr) 2009-01-15
KR101625234B1 (ko) 2016-05-30
PH12018502038A1 (en) 2019-08-19
IL223108B (en) 2019-06-30
HK1193620A1 (zh) 2014-09-26
WO2009007427A3 (fr) 2009-04-09
EP2014681A1 (fr) 2009-01-14
IL223106B (en) 2020-06-30
US8871910B2 (en) 2014-10-28
PT2188312E (pt) 2015-10-05
BRPI0815564B8 (pt) 2021-05-25
JP2014113155A (ja) 2014-06-26
HRP20150887T1 (hr) 2015-09-25
EP2415785A1 (fr) 2012-02-08
CA2981821C (fr) 2020-07-28
US20100115639A1 (en) 2010-05-06
TW201605892A (zh) 2016-02-16
SG183015A1 (en) 2012-08-30
ZA201000966B (en) 2011-02-23
MY158756A (en) 2016-11-15
SI2188312T1 (sl) 2015-09-30
AU2008274171A1 (en) 2009-01-15
CA2694418C (fr) 2018-03-27
CY1116608T1 (el) 2017-03-15
KR101701686B1 (ko) 2017-02-01
KR20160019975A (ko) 2016-02-22
NZ599959A (en) 2013-11-29
TWI602830B (zh) 2017-10-21
CN103183739B (zh) 2016-08-17
PH12018502039A1 (en) 2019-08-19
KR20160019974A (ko) 2016-02-22
US8871909B2 (en) 2014-10-28
SA08290423B1 (ar) 2013-12-23
CO6170364A2 (es) 2010-06-18
US20130280257A1 (en) 2013-10-24
US9107907B2 (en) 2015-08-18
TN2010000016A1 (en) 2011-09-26
EP2535357B1 (fr) 2018-08-08
TW201437231A (zh) 2014-10-01
EP2535356A1 (fr) 2012-12-19
CA2981821A1 (fr) 2009-01-15
IL223105A0 (en) 2012-12-31
MX345391B (es) 2017-01-27
CN101981054B (zh) 2015-04-15
PH12018502040A1 (en) 2019-08-19
RS54197B1 (en) 2015-12-31
IL223108A0 (en) 2012-12-31
ES2693542T3 (es) 2018-12-12
JP2014113153A (ja) 2014-06-26
EP2188312A2 (fr) 2010-05-26
WO2009007427A2 (fr) 2009-01-15
JP5889925B2 (ja) 2016-03-22
ES2542059T3 (es) 2015-07-30
ES2686335T3 (es) 2018-10-17
CL2008002015A1 (es) 2008-11-21
KR101719084B1 (ko) 2017-03-22
AR109535A2 (es) 2018-12-19
PL2188312T3 (pl) 2016-01-29
TWI592427B (zh) 2017-07-21
CN101981054A (zh) 2011-02-23
IL223109A0 (en) 2012-12-31
EP2535357A1 (fr) 2012-12-19
CN103183739A (zh) 2013-07-03
NZ583041A (en) 2012-06-29
CN103509112A (zh) 2014-01-15
BRPI0815564B1 (pt) 2020-01-21
KR101701685B1 (ko) 2017-02-01
US20150252114A1 (en) 2015-09-10
TWI549965B (zh) 2016-09-21
JP5889924B2 (ja) 2016-03-22
US20130272957A1 (en) 2013-10-17
TW200911828A (en) 2009-03-16
EP2415785B1 (fr) 2018-04-25
CN103509112B (zh) 2015-10-21
NZ613716A (en) 2015-01-30
HUE026026T2 (en) 2016-05-30
AR109659A2 (es) 2019-01-09
CN103509113A (zh) 2014-01-15
US8329173B2 (en) 2012-12-11
MX341012B (es) 2016-08-03
JP5889923B2 (ja) 2016-03-22
US8889832B2 (en) 2014-11-18
ES2678495T3 (es) 2018-08-13
EP2415784A1 (fr) 2012-02-08
CN103509113B (zh) 2015-10-21
CA2982484C (fr) 2021-06-01
IL223105B (en) 2020-02-27
BRPI0815564A2 (pt) 2015-02-18
IL223109B (en) 2019-06-30
US20130273060A1 (en) 2013-10-17
JP2010532982A (ja) 2010-10-21
JP5562844B2 (ja) 2014-07-30
AR067517A1 (es) 2009-10-14
ME02341B (fr) 2015-12-31
EP2188312B1 (fr) 2015-05-27
US20140010818A1 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
IL223105A0 (en) Novel antibodies inhibiting c - met dimerization, and uses thereof
IL252561A0 (en) Antibodies against Siglac-15 polynucleotides encoding them, preparations containing them and their uses
HK1158229A1 (en) C-met antibodies c-met
GB0708002D0 (en) Antibodies
EP2089034A4 (fr) Nouvelles utilisations
SI2200700T1 (sl) Nova protitelesa
HK1136970A1 (en) Penta-specific antibody
EP2138576A4 (fr) Anticorps anti-claudine-4
GB0525251D0 (en) Oligomerisation
GB0702888D0 (en) Novel Antibodies
GB0718737D0 (en) Antibodies
IL205073A0 (en) Anti-bst2 antibody
EP2351732A4 (fr) Nouveau composé de ramaline et utilisation de celui-ci
IL200863A0 (en) Novel uses
MX281289B (es) Hidrocarburos.
GB0820231D0 (en) Airbagmodul, airbagmodulanordung und befestigungsverfahren
HK1142342A1 (en) Cyclic, cystein-free protein
IL204171A (en) An enzyme strain of the staphylocinase family
GB0715036D0 (en) Shoulder elimination
GB0724185D0 (en) Antibodies
GB0704284D0 (en) Es,e-o hi-grip peel-n-seal